PlainRecalls
FDA Drug Moderate Class II Ongoing

Belsomra (suvorexant) tablets, 10mg, 30 Tablets in 3 Blister Cards per Carton, Each Blister Card contains 10 Tablets, Rx only, Merck Sharp & Dohme LLC, Rahway, NJ 07065, USA, NDC 0006-0033-10 (Shellpack and Print Mat Labels), 0006-0033-30 (Carton Label)

Reported: August 20, 2025 Initiated: July 21, 2025 #D-0584-2025

Product Description

Belsomra (suvorexant) tablets, 10mg, 30 Tablets in 3 Blister Cards per Carton, Each Blister Card contains 10 Tablets, Rx only, Merck Sharp & Dohme LLC, Rahway, NJ 07065, USA, NDC 0006-0033-10 (Shellpack and Print Mat Labels), 0006-0033-30 (Carton Label)

Reason for Recall

Failed Dissolution Specifications: potential for delayed dissolution of the dose after administration which may result in delayed release of the drug, delaying onset of sleep.

Details

Recalling Firm
Merck & Co. Inc
Units Affected
51,320 cartons
Distribution
Nationwide in the USA and PR.
Location
Rahway, NJ

Frequently Asked Questions

What product was recalled?
Belsomra (suvorexant) tablets, 10mg, 30 Tablets in 3 Blister Cards per Carton, Each Blister Card contains 10 Tablets, Rx only, Merck Sharp & Dohme LLC, Rahway, NJ 07065, USA, NDC 0006-0033-10 (Shellpack and Print Mat Labels), 0006-0033-30 (Carton Label). Recalled by Merck & Co. Inc. Units affected: 51,320 cartons.
Why was this product recalled?
Failed Dissolution Specifications: potential for delayed dissolution of the dose after administration which may result in delayed release of the drug, delaying onset of sleep.
Which agency issued this recall?
This recall was issued by the FDA Drug on August 20, 2025. Severity: Moderate. Recall number: D-0584-2025.